Rapport Therapeutics, Inc Common Stock
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $0 | $20,000 | $0 | $0 |
Gross Profit | 20,000 | -265 | -256 | |
EBITDA | -56,176 | -23,988 | -38,244 | -29,730 |
EBIT | -56,615 | -24,215 | -38,509 | -29,986 |
Net Income | -56,615 | -19,857 | -33,763 | -26,925 |
Net Change In Cash | 0 | 20,000 | 0 | 0 |
Free Cash Flow | -54,680 | -13,147 | -24,870 | -17,599 |
Cash | 63,612 | 78,056 | 52,645 | 251,359 |
Basic Shares | 47,473 | 47,236 | 46,978 | 37,931 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
Revenue | $0 | $0 | $0 |
Gross Profit | -1,016 | -839 | -112 |
EBITDA | -124,082 | -82,216 | -36,067 |
EBIT | -125,099 | -83,055 | -36,179 |
Net Income | -111,483 | -78,307 | -34,786 |
Net Change In Cash | 0 | 0 | 0 |
Free Cash Flow | -88,089 | -67,233 | -28,817 |
Cash | 52,645 | 56,805 | 70,169 |
Basic Shares | 46,978 | 20,738 | 18,078 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$1.19 |
2026-03-31 | -$0.42 |
2025-12-31 | -$0.72 |
2025-09-30 | -$0.71 |